{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:bulk laxative bran
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03557008: Phase 4 Interventional Completed Rabies Human
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE